Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Dexamethasone in Rosai-Dorfman Disease
NCT07187167Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in Rosai-Dorfman disease (RDD), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Apr 2025; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
Rosai-Dorfman disease (RDD)
Beyond the preview
Go deeper on NCT07187167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187167.